Endocrine and metabolic abnormalities following kidney transplantation
- PMID: 2681969
- DOI: 10.1007/BF01717348
Endocrine and metabolic abnormalities following kidney transplantation
Abstract
Various endocrine and metabolic disturbances associated with long standing uremia persist after kidney transplantation or arise from the use of immunosuppressive drugs. Hyperlipidemia for long time being implicated as the cause of corticosteroids is also observed in renal transplant recipients treated with cyclosporin A monotherapy. After conversion from cyclosporin to azathioprine serum cholesterol and triglyceride concentration fall, and elevation of LDL-cholesterol may also be reversed. There is a tendency for higher HDL-cholesterol in azathioprine and prednisolone treated transplant patients. Those patients who are at risk for clinically significant cholesterol elevations can be predicted by their pretransplant lipid levels, specifically the LDL-fraction. Risk-benefit ratio of conversion and of treatment with lipid-lowering drugs, especially with lovastatin, should be carefully examined, also in view of glucose intolerance. Higher incidence of diabetes mellitus requiring insulin therapy in cyclosporin treated transplant recipients has been reported. Cyclosporin may cause toxic effects on pancreatic beta-cells resulting in inhibition of insulin secretion. High doses of cyclosporin induce inhibition of glycogen synthesis in rat liver. Glucose intolerance is reversible after reduction of cyclosporin dose or conversion to azathioprine. Therefore glucose metabolism in kidney transplant recipients treated with cyclosporin should be carefully followed. Immunosuppressive therapy may affect reproductive function, arachidonate metabolism and renin-angiotensin-aldosterone system as well as posttransplant calcium and phosphate metabolism. Endocrine and metabolic abnormalities are associated with long standing uremia. After successful kidney transplantation several observations are normalized but further complications arise from the use of immunosuppressive drugs. The present paper reviews various endocrine and metabolic disturbances described following renal transplantation.
Similar articles
-
Endocrine-metabolic pathophysiologic conditions and treatment approaches after kidney transplantation.Endocr Pract. 2012 Jul-Aug;18(4):579-90. doi: 10.4158/12016.RA. Endocr Pract. 2012. PMID: 22849872 Review.
-
Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation.Nephron. 1997;75(3):277-82. doi: 10.1159/000189549. Nephron. 1997. PMID: 9069448
-
Impact of fluvastatin on hyperlipidemia after renal transplantation.Transplant Proc. 2004 Sep;36(7):2141-4. doi: 10.1016/j.transproceed.2004.06.027. Transplant Proc. 2004. PMID: 15518777 Clinical Trial.
-
Dyslipoproteinemia in renal transplantation.J Postgrad Med. 1994 Jan-Mar;40(1):10-2. J Postgrad Med. 1994. PMID: 8568706
-
Post-transplant diabetes mellitus. The role of immunosuppression.Drug Saf. 1997 Apr;16(4):242-57. doi: 10.2165/00002018-199716040-00002. Drug Saf. 1997. PMID: 9113492 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Medical